Neuralink

The 29-year-old patient who was paralyzed below the shoulder after a diving accident, played chess on his laptop and moved the cursor using the Neuralink device.

Large volumes of diabetes drug Ozempic are not being exported from Germany, its health ministry said, quashing a suggestion by its drugs regulator that outbound trade in the drug, coveted for its weight-loss effect, may have to be banned.

The site, designed to produce large-scale biologics for Roche’s Genentech, will help Lonza meet the demand for commercial mammalian products from other companies and make molecules in development

Bayer

The deal involves a partnership to develop next-generation sequencing (NGS)-based companion diagnostic assays (CDx) together. These will help identify patients who may benefit from Bayer’s growing portfolio of precision cancer therapies by offering decentralized genomic testing and rapid turnaround time.

BMS, Bristol Myers Squibb

Bristol Myers Squibb secured another late-phase immuno-oncology victory Wednesday, showing that the combination of Opdivo and Yervoy improved overall survival in a patient population served by rival checkpoint inhibitors from AstraZeneca and Roche.

pharmaceuticals

Orchard Therapeutics, a unit of Japan’s Kyowa Kirin , priced its newly approved gene therapy for a rare, life-threatening genetic disease on Wednesday at $4.25 million, making it the most expensive drug in the United States.

Takeda secured another label expansion for the kinase inhibitor, this time in the first-line setting for the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia.

Since Roche’s Zelboraf gained (vemurafenib) FDA approval in 2011, significant strides have been made in BRAF-targeted cancer therapies, underscoring the significance of combating BRAF mutations in melanoma. Against this backdrop, Pfizer’s Braftovi (encorafenib) is positioned to secure a dominant 42% share of the BRAF inhibitors market for melanoma by 2028, underscoring its pivotal role in cancer therapy.

BioNTech

The company posted revenues of 3.819 billion euros ($4.14 billion), down by more than three-quarters compared to 2022, and net profit of 930.3 million euros, 90% lower than a year earlier.

EU, European Union

Lawmakers in a EU parliamentary committee on Tuesday voted to extend the exclusivity period for new medicines compared to an initial draft, seeking to address concerns expressed across the bloc’s pharma industry as part of a wider regulatory overhaul.